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Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is
an uncommon subtype of Hodgkin lymphoma (HL) (Morton et al.,
2006). Extranodal involvement is a rare presentation of NLPHL
(Shimabukuro-Vornhagen et al., 2005). In this report, we describe a
case of NLPHL involving the uterine cervix in a 54-year-old woman
who was treated with deﬁnitive radiation therapy (RT).
Case report
A54-year-old healthy female,whohas previously underwent subtotal
hysterectomy with preservation of the cervix for treatment of uterine
ﬁbroids, presented with persistent vaginal bleeding. She has had two
satisfactory Pap smears, dating 1 and 4 years prior to her presentation,
both of which were negative for intraepithelial lesion or malignancy.
Pelvic examination revealed a cervical mass. Endocervical curettage and
a biopsy were performed and an enhanced computed tomography (CT)
scan of the abdomen and pelvis was requested. The scan revealed
enlargement of the cervix (Fig. 1(a)), associated with pelvic and inguinal
lymphadenopathy.
Pathological examination of the endocervical curettage revealed
lymphoid inﬁltration, consistent with a lymphoma (Fig. 2(a)). Despite
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(Fig. 2(b)). On high magniﬁcation, the lymphoid nodules were popu-
lated by benign small lymphocytes, admixed with scattered large
abnormal-appearing lymphoid cells with features highly suggestive of
lymphocytic and histiocytic (L&H) Reed-Sternberg (RS) cells (Fig. 3).
Immunohistochemical studies revealed that these cells were positive
for CD20 (Fig. 4(a)), CD45, PAX5, BCL-6, BOB1 (Fig. 4(b)) and OCT2
(Fig. 4(c)). They were dimly positive or negative for CD30; no detect-
able expression for BCL-2, CD10, or CD3 and epithelial membrane anti-
gen (EMA)was found. The background T cells were positive for CD3 and
CD4, and a subset was positive for CD57. These large cells were rimmed
with CD57-positive small T-cells. A good number of CD20-positive small
B-cells were also found. Considering the overall morphological and
immunophenotypic pattern, the diagnosis was felt to be NLPHL. In
view of the unusual clinical presentation, a decision to obtain additional
tissue biopsy was made. The repeat biopsy showed lymphoid cells ar-
ranged in a vaguely nodular pattern with scattered L&H cells. Rimming
with CD3-positive T-cells was again noted (Fig. 4(d)). The remainder of
the immunohistochemical studies revealed similar ﬁndings to those in
the ﬁrst biopsy. A diagnosis of NLPHL arising in the cervix was conferred.
A positron emission tomography (PET)-CT (Fig. 1(b)) revealed
abnormal metabolic activity within the cervical mass, left inguinal
lymph nodes (LNs) and bilateral common and external iliac LNs.
Baseline blood investigations were unremarkable. The patient was
designated Stage IIEA based on the Ann Arbour staging system. The
treatment plan was discussed by our multidisciplinary lymphoma
team and treatment with radiation alone was elected. The patient
underwent CT simulation. The gross tumour volume (GTV) was
deﬁned as the disease identiﬁed on CT and PET-CT. The ﬁrst clinical
target volume (CTV1) included the cervix, para-aortic, bilateral
common iliac, external iliac and inguinal LNs. This was treated to
40 Gy in 20 fractions using 15MV anterior and posterior photon ﬁelds,
shielding normal structures when possible. The patient tolerated the
treatment well and considerable response to RT was noted after
3 weeks, following which she underwent another CT simulation.
Residual disease was limited to the cervical remnant and this consti-
tuted the CTV2 which was treated to an additional 10 Gy using 15
MV photons and a four-ﬁeld box technique. Toward the end of the
treatment, the patient developed grade 2 radiation dermatitis, grade
1 nausea and vomiting and grade 1 diarrhea.
The patient was clinically evaluated 2 months following the
completion of RTwhen shewas found to have recovered from radiation
side effects. There was no evidence of residual disease but a 1.5 cmlicense.
Fig. 1. (a) Contrast-enhanced computed tomography (CT) of a 54-year-old woman who presented with vaginal bleeding with remote history of subtotal hysterectomy with
evidence of a large tumour of the residual cervix on pelvic examination. It shows an 8-cm cervical mass with smooth borders (solid long white arrow), a left external iliac
lymph node (LN) (black arrow), a right external iliac LN (dashed white arrow), and a right internal iliac LN (solid short white arrow). (b) Positron emission tomography-CT
scan showing increased metabolic activity in cervical mass (black arrow), a right internal iliac LN (solid white arrow) and a left external iliac lymph node (LN) (dashed white
arrow).
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ously large malignancy was observed. A CT scan of the chest, abdomen
and pelvis also indicated complete response to radiotherapy. Subse-
quent evaluation, 5 months from RT, showed complete healing of the
vaginal ulcer. The patient remains alive and in remission one and a
half year since her diagnosis with no signiﬁcant morbidity.
Discussion
NLPHL compromises 5% of all cases of HL, with classical Hodgkin
lymphomas (CHL) being the more common subtype (IARC, 2008). It
is a rare disease with an incidence of 0.08/100,000 people/year in
the Unites States (Morton et al., 2006). The median age at diagnosis
is 37 years and 75% of patients are males (Nogova et al., 2005).
Efforts to identify this morphologically distinct subtype of HL are
worthwhile considering its different biological and clinical behaviors.
Based on themost comprehensive comparison with CHL, NLPHL carries
a more favorable prognosis (Nogova et al., 2008). The characteristic
malignant cell, the lymphocytic and histiocytic (L&H) cell, is an atypical
variant of Reed–Sternberg (RS) cell; L&H cells typically have vesicular,
polylobulated nuclei and distinct small, peripheral nucleoli. The nuclear
appearance resembles exploded popcorn, from which the term
“popcorn cells” stems. These cells are present in a background of trans-
formed follicles giving rise to the characteristic nodular architecture.
Background cells consist of small B-lymphocytes, follicular dendritic
cells, and follicular CD57+ T cells (IARC, 2008; Nogova et al., 2006). TheFig. 2. (a) Endocervical curettage showing cervical glands surrounded by a dense lympho
pattern of the lymphoid cells was noted (haematoxylin and eosin ×100).characteristic L&H cellswere identiﬁed in our patient but the nodular pat-
ternwas vague. However, a partly nodular pattern is considered adequate
for establishing the diagnosis as per the WHO deﬁnition of NLPHL (IARC,
2008). Such as other lymphoma types, immunophenotyping plays a
major role in establishing the diagnosis. The L&H cells are CD45 and
BCL-6 positive and classically express B-cell antigens such as CD19,
CD20, CD22, and CD79a. Unlike their counterparts, RS cells in CHL,
these cells are usually negative for CD15 and CD30. The EMA, BOB-1,
OCT-2 are positive in NLPHL and these supplementary markers aid
establishing the diagnosis in difﬁcult cases. Background T-cells are usual-
ly positive for CD3, CD4 or CD57 and the follicular dendritic cells are usu-
ally positive for CD21 and CD23 (IARC, 2008; Nogova et al., 2006). With
the exception of CD21-, CD23-positive dendritic cells, the characteristic
immunophenotypic pattern of NLPHL was reproduced in our patient.
Patients with NLPHL classically present with peripheral lymph-
adenopathy, with the neck being the most commonly involved site.
Mediastinal involvement is rare. Splenomegaly is seen in 8% of patients
and involvement of organs such as the liver, bone marrow, lungs or
skeleton occurs in b5% (2). In our patient, the primary disease bulk
was extranodal and to our knowledge, no cases of NLPHL of the cervix
have been previously reported in the literature. Mihaljevic et al.
reported a case of 69-year-old female who developed a relapse of
CHL, a nodular sclerosis subtype, in the cervix. The patient initially
presented with disseminated disease and was treated with chemother-
apy followed by extended-ﬁeld (EF) RT. She remained in complete
remission for 15 years but then the disease recurred with solitarycytic inﬁltrate (haematoxylin and eosin ×100). (b) Focally, a vaguely nodular growth
Fig. 3. (a)Uterine cervix biopsy showing a cervical gland surroundedby amixture of large lymphoid cells andbenign-appearing small lymphocytes (haematoxylin andeosin×400). (b)Uterine
cervix biopsy showing the presence of large abnormal-appearing lymphoid cellswith polylobulated nuclei (popcorn cell), highly suggestive of lymphocytic and histiocytic Reed–Sternberg cells
(haematoxylin and eosin ×1000).
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patient died due to renal failure (Mihaljevic et al., 2008). On the other
hand, despite remaining a rare event, more cases of non-Hodgkin
lymphoma involving the female genital tract have been described in
the literature with secondary extension in disseminated disease seen
more often than primary disease presentation in the cervix (Upanal
and Enjeti, 2011).
In the absence of randomized controlled trials, caused by the rarity
of the disease and the low event rate in these patients, the optimal
treatment of early-stage NLPHL remains unclear (Nogova et al.,
2008). For patients with stage IA and IIA NLPHL, treatment options
include extended- or involved-ﬁeld RT with or without chemotherapy
(Nogova et al., 2005). The largest reported experience comes from the
Australasian Radiation Oncology Lymphoma Group (Wirth et al.,
2005). In this study, the long-term outcome of 202 patients with stage
IA–IIA NLPHL treated with EF RT was analyzed. The 15-year overall
survival (OS) was 83%, and freedom from progression rate was 84%
for stage I disease and 73% for stage II disease. Causes of death were
NLPHL, NHL, in-ﬁeld malignancy or in-ﬁeld cardiac/respiratory compli-
cations. The authors concluded that RT alone is potentially curative in
early-stage NLPHL and suggested that involved-ﬁeld (IF) RT might be as
efﬁcacious. A recent analysis of 113 patients with stage I-II NLPHL
addressed the question about the optimal RT volume (Chen et al.,
2010). In this study, 93 patients received RT alone, 13 received RT with
chemotherapy, and 7 received chemotherapy alone. Limited-ﬁeld,
regional-ﬁeld and EF RT were used. Both progression-free survival and
OS did not differ with the extent of irradiated volume. The study also
demonstrated the crucial role of RT as inferior outcomes were observed
with chemotherapy alone. The adequacy of IF RT in stage IA disease was
also demonstrated in a retrospective analysis by the German Hodgkin
Study Group (GHSG) (Nogova et al., 2005). In 131 patients treated with
EF RT, IF RT or combinedmodality (CM), the freedom from treatment fail-
ure and OS rates were 95% and 99%, respectively. The rate ofWHO Grade
3 toxicity was greater with CM treatment. Supported by the aforemen-
tioned evidence, our patient was treated with RT alone. A total dose of
50 Gy was delivered, driven by the bulk of her disease and by the well
established tolerance of the cervix and vaginal tissue to such a dose.
Two recent studies contribute to deﬁning the role of systemic therapy
in early-stage NLPHL. The ﬁrst is a retrospective analysis of 88 patients
treated with RT, ABVD-like chemotherapy followed by RT or ABVD only.
The 10-year PFS (91% vs. 65%) and the OS (93% vs. 84%) favoured com-
bined treatment with ABVD (Savage et al., 2011). The second is a phase
II study examining the use Rituximab in stage IA NLPHL (Eichenauer et
al., 2011). Despite the inferior outcome with Rituximab alone (3-year
PFS of 81%), this study helps directing future research that aims at re-
ducing treatment related-side effects in these long-term survivors.Conclusion
This report describes a rare presentation of a rare disease. The
complete response to RT in this patient is consistentwith the expected
clinical behavior of NLPHL. The optimal management of NLPHL con-
tinues to evolve with the search of an effective treatment regimen
that carries the lowest long-term side effects.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.gynor.2012.11.001.
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